Administrative Core

行政核心

• 批准号: 8540392
• 负责人: JOSEPH M. DESIMONE
• 金额: $ 15.24万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8540392
• 关键词: Adherence; Area; Arts; Award; Basic Science; Breast; Budgets; CCNE1 gene; Caliber; Cancer Center; Cancer Patient; Clinic; Clinical; Clinical Sciences; Communication; Communities; Consultations; Dependency; Development; Disease Management; Doctor of Medicine; Doctor of Philosophy; Drug Delivery Systems; Education and Outreach; Effectiveness; Electronic Mail; Ensure; Environment; Funding; General Population; Goals; Institutes; Institution; Laboratories; Leadership; Malignant Neoplasms; Medical; Nanotechnology; North Carolina; Patient Care; Pharmacy Schools; Pharmacy facility; Play; Principal Investigator; Public Health; Recording of previous events; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Role; Schedule; Schools; Science; Scientist; Solutions; Specialized Program of Research Excellence; Technology; TimeLine; Translational Research; UNC Lineberger Comprehensive Cancer Center; Universities; Update; Work; anticancer research; drug development; experience; fight against; innovation; interest; medical schools; meetings; member; multidisciplinary; nanofabrication; nanomaterials; nanomedicine; nanoparticle; nanoscience; oncology; physical science; programs; success; web site; working group

Section N2. Research Team and Research Capabilities, Center Organization and Infrastructure (Administrative Core) 1) Research Team Outline the major strength of the team and specific senior investigators In the context of the proposed area of focus; Successful application of nanotechnology to cancer requires an interactive and diverse team with innovative and creative solutions. The innovation and goals proposed In our CCNE are challenging but mirror the strength of our researchers and partnerships, especially since our focus is to transition these nanotechnologies to cancer disease management. Our team reflects that focus and combines expertise in the basic science of nanotechnology working In concert with translational research oriented clinicians who can help both the broad and the specific research agenda to maximize a direct impact on patient care. In addition, we have successfully combined researchers from four schools on the UNC campus: the Schools of Medicine, Arts and Sciences, Pharmacy and Public Health. This diversity of expertise and interests will help to ensure the success of our program. Our research team is led by Co-Principal Investigators, Joseph M. DeSimone, Ph.D. and Joel Tepper, M.D., who bring extensive experience in scientific leadership across the continuum from basic science to clinical development. We have emphasized this bridging of basic and clinical sciences throughout our proposal to demonstrate our understanding of and commitment to the challenge of bringing nanotechnology applications to cancer patients. Our projects feature nanotechnologies that are singular to the University of North Carolina at Chapel Hill, build on innovative ideas that have originated within our group, and reflect the highest caliber of scientists who discovered and developed them. We are confident that our mix of ideas, people and technologies is ideally suited to deliver on the promise of Nanomedicine. The University of North Carolina at Chapel Hill prides itself on being a leading institute in both medical and physical sciences and also providing and facilitating an environment of inter-disciplinary interactions. The cancer research community at UNC is anchored by the UNC Lineberger Comprehensive Cancer Center with a 35-year history. It is further strengthened by the presence of two NCI Specialized Programs of Research Excellence (SPOREs) in Breast and Gl cancer. The physical sciences aspects of our center are supported by the newly formed Institute for Nanomedicine, the Institute for Advanced Materials, Nanoscience and Technology (lAM) and the Chapel Hill Analytical and Nanofabrication Laboratory (CHANL). The Center for Nanotechnology in Drug Delivery and the Translational Oncology and Nanoparticle Drug Development Initiative (TONDDI) Lab at the Eshelman School of Pharmacy help transition nanomaterial discoveries toward the clinic. The $50 million/year University Cancer Research Fund (UCRF) and UNC's Clinical and Translational Science Award (CTSA) further enhance the entrepreneurial and translational aspects of our efforts of bringing relief to cancer patients. Our Center leadership will have all these resources to support a cohesive, stimulating, and effective CCNE. Our team and resources are discussed in more detail in the following sections.

第N2节。研究团队和研究能力，中心组织和基础设施 （行政核心） 1）研究团队在拟议的重点领域的背景下概述了团队和特定高级研究人员的主要优势； 纳米技术在癌症中的成功应用需要具有创新和创造性解决方案的互动和多样化的团队。我们CCNE提出的创新和目标具有挑战性，但反映了我们的研究人员和伙伴关系的力量，尤其是因为我们的重点是将这些纳米技术转变为癌症疾病管理。我们的团队反映了专注于纳米技术基础科学的专业知识，并与以转化研究为导向的临床医生共同工作，这些临床医生都可以帮助广泛 以及最大化直接影响患者护理的特定研究议程。此外，我们已经成功地结合了UNC校园四所学校的研究人员：医学，艺术和科学，药学和公共卫生。这种专业知识和利益的多样性将有助于确保我们计划的成功。 我们的研究团队由联合主持调查员Joseph M. Desimone博士领导。以及医学博士乔尔·特珀（Joel Tepper），他们在从基础科学到临床发展的连续性方面具有丰富的科学领导力经验。我们在我们的提案中强调了基础和临床科学的这种桥接，以表明我们对将纳米技术应用程序提出的挑战的理解和承诺 癌症患者。我们的项目采用纳米技术对北卡罗来纳大学教堂山分校的奇异性，建立在我们小组中的创新思想，并反映了发现和开发它们的科学家的最高水平。我们相信，我们的思想，人和技术的混合方式非常适合兑现纳米医学的希望。 北卡罗来纳大学教堂山分校以医学和物理科学领域的领先研究所而自豪，还提供和促进了跨学科互动的环境。 UNC的癌症研究界由UNC Lineberger综合癌症中心锚定了35年的历史。在乳腺癌和GL癌中，有两个NCI专业研究计划（孢子）的存在进一步加强。我们中心的物理科学方面得到了支持 新成立的纳米医学研究所，高级材料研究所，纳米科学技术研究所（LAM）以及教堂山分析和纳米制造实验室（Chanl）。埃塞尔曼药学院的药物输送和纳米颗粒药物开发计划（TONDDI）实验室的纳米技术中心在埃塞尔曼药学院有助于过渡纳米材料的发现。耗资5000万美元的大学癌症研究基金（UCRF）和UNC的临床与转化科学奖（CTSA）进一步增强了我们为癌症患者救济而努力的企业家和转化方面。我们的中心领导将拥有所有这些资源，以支持凝聚力，刺激和有效的CCNE。在以下各节中，更详细地讨论了我们的团队和资源。